# TAT Technologies (TATT) — News

TATT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/tatt/news

## Recent headlines

- [Tata Technologies - Remain confident in delivering strong double-digit growth for full year](https://www.ainvest.com/news/tata-technologies-remain-confident-delivering-strong-double-digit-growth-full-year-2610) — AInvest Wire, Oct 14, 2026
- [Circuit breaker: CIFC (BATS) - Volatility trading pause](https://www.ainvest.com/news/circuit-breaker-cifc-bats-volatility-trading-pause-2610) — AInvest Wire, Oct 13, 2026
  On October 13, 2026, trading in CIFC (BATS) was temporarily paused due to a circuit breaker mechanism designed to manage excessive volatility in the stock market. Circuit breakers are pre-defined thresholds that trigger trading halts when price movements exceed specified levels within a given…
- [Al Tajamouat for Touristic Projects - Acquisition as part of commitment to completing its development and expansion plans](https://www.ainvest.com/news/al-tajamouat-touristic-projects-acquisition-part-commitment-completing-development-expansion-plans-2610) — AInvest Wire, Oct 13, 2026
  Al Tajamouat for Touristic Projects Company PSC (TAJM), a Jordan-based public shareholding company operating in the real estate development and operations sector, has recently made a strategic acquisition as part of its ongoing commitment to completing its development and expansion plans. The…
- [Tavexia Lifecare - Board approves acquisition of 60% controlling stake in Meyonex Pharmaceuticals](https://www.ainvest.com/news/tavexia-lifecare-board-approves-acquisition-60-controlling-stake-meyonex-pharmaceuticals-2610) — AInvest Wire, Oct 12, 2026
  Tavexia Lifecare Limited (TAVX) has announced that its board of directors has approved the acquisition of a 60% controlling stake in Meyonex Pharmaceuticals. The move is expected to strengthen Tavexia’s position in the pharmaceutical sector by expanding its product portfolio and enhancing its…
- [First Tracks Biotherapeutics shares rise 13.3% premarket after positive results from celiac disease drug trial](https://www.ainvest.com/news/tracks-biotherapeutics-shares-rise-13-3-premarket-positive-results-celiac-disease-drug-trial-2610) — AInvest Wire, Oct 12, 2026
  First Tracks Biotherapeutics Inc. (NASDAQ: FTBT) reported a 13.3% increase in premarket trading on October 12, 2026, following the release of positive clinical trial results . The company announced that the drug demonstrated a favorable safety profile and showed measurable efficacy in reducing…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).